Back to Results
First PageMeta Content
Pharmacology / Afamelanotide / Erythropoietic protoporphyria / Melanocyte-stimulating hormone / Actinic keratosis / Squamous-cell carcinoma / Urticaria / Biopharmaceutical / Pharmaceutical industry / Medicine / Peptide hormones / Oncology


Document Date: 2012-04-19 14:38:23

Open Document

File Size: 46,09 KB

Share Result on Facebook

City

San Francisco / Zürich / /

Company

Clinuvel Pharmaceuticals Limited / Corporate Development Clinuvel Pharmaceuticals Limited / /

/

Event

FDA Phase / /

IndustryTerm

biopharmaceutical / cancer treatment / active pharmaceutical substance / pharmaceutical products / acknowledged pharmaceuticals / pharmaceutical identifier / /

MedicalCondition

anaphylactic reaction / Actinic Keratosis / Squamous Cell Carcinoma / cancer / Recipients (OTR) Solar Urticaria / Phototoxicity / Erythropoietic Protoporphyria / UV-related skin disorders / /

MedicalTreatment

Photodynamic Therapy / Organ Transplant / radiation / /

Organization

World Health Organisation / Melbourne Australia World Health Organisation / /

Person

Philippe Wolgen / /

/

Position

CEO / Colin Mackie Head / /

Product

CUV1647 / on developing its photo-protective drug / CUV1647 / /

Technology

alpha / radiation / /

SocialTag